Baek-Yeol Ryoo - Search Results

Year	Number of Results
2002	3
2004	3
2005	6
2006	11
2007	19
2008	16
2009	8
2010	10
2011	10
2012	11
2013	9
2014	7
2015	22
2016	18
2017	22
2018	24
2019	19
2020	26
2021	31
2022	13
2023	14
2024	12

1

Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.

Chan SL, Ryoo BY, Mo F, Chan LL, Cheon J, Li L, Wong KH, Yim N, Kim H, Yoo C. Chan SL, et al. Among authors: ryoo by. J Hepatol. 2024 Apr 1:S0168-8278(24)00216-2. doi: 10.1016/j.jhep.2024.03.033. Online ahead of print. J Hepatol. 2024. PMID: 38570034

2

Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer.

Lee W, Oh M, Kim JS, Sung M, Hong K, Kwak BJ, Park Y, Jun E, Song KB, Hwang DW, Lee JH, Yoo C, Kim KP, Park I, Jeong JH, Chang HM, Ryoo BY, Lee JB, Kim SC. Lee W, et al. Among authors: ryoo by. Int J Surg. 2024 Mar 28. doi: 10.1097/JS9.0000000000001389. Online ahead of print. Int J Surg. 2024. PMID: 38537071

3

Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma.

Yoon H, Shin Y, Ryoo BY, Jeong H, Park I, Seo DW, Lee SS, Park DH, Song TJ, Oh D, Hwang DW, Lee JH, Song KB, Park Y, Kwak BJ, Hong SM, Park JH, Kim SC, Kim KP, Yoo C. Yoon H, et al. Among authors: ryoo by. Pancreatology. 2024 May;24(3):424-430. doi: 10.1016/j.pan.2024.02.004. Epub 2024 Feb 19. Pancreatology. 2024. PMID: 38395676

4

Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial.

Kim HD, Jung S, Lim HY, Ryoo BY, Ryu MH, Chuah S, Chon HJ, Kang B, Hong JY, Lee HC, Moon DB, Kim KH, Kim TW, Tai D, Chew V, Lee JS, Finn RS, Koh JY, Yoo C. Kim HD, et al. Among authors: ryoo by. Nat Med. 2024 Mar;30(3):699-707. doi: 10.1038/s41591-024-02824-y. Epub 2024 Feb 19. Nat Med. 2024. PMID: 38374347 Free PMC article. Clinical Trial.

5

Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors.

Kim JY, Kim J, Kim YI, Yang DH, Yoo C, Park IJ, Ryoo BY, Ryu JS, Hong SM. Kim JY, et al. Among authors: ryoo by. Sci Rep. 2024 Feb 19;14(1):4047. doi: 10.1038/s41598-024-54599-4. Sci Rep. 2024. PMID: 38374188 Free PMC article.

6

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.

Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L. Yau T, et al. Among authors: ryoo by. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):310-322. doi: 10.1016/S2468-1253(23)00454-5. Epub 2024 Feb 13. Lancet Gastroenterol Hepatol. 2024. PMID: 38364832 Clinical Trial.

7

Prediction of [¹⁷⁷Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [¹⁷⁷Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour.

Ha S, Kim YI, Oh JS, Yoo C, Ryoo BY, Ryu JS. Ha S, et al. Among authors: ryoo by. EJNMMI Phys. 2024 Feb 5;11(1):14. doi: 10.1186/s40658-024-00620-8. EJNMMI Phys. 2024. PMID: 38315270 Free PMC article.

8

Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors.

Kang YK, Ryu MH, Hong YS, Choi CM, Kim TW, Ryoo BY, Kim JE, Weis JR, Kingsford R, Park CH, Jang S, McGinn A, Werner TL, Sharma S. Kang YK, et al. Among authors: ryoo by. Cancer Res Treat. 2024 Jan 18. doi: 10.4143/crt.2023.980. Online ahead of print. Cancer Res Treat. 2024. PMID: 38271925 Free article.

9

Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study.

Piscaglia F, Ikeda K, Cheng AL, Kudo M, Ikeda M, Breder V, Ryoo BY, Mody K, Ren M, Ramji Z, Sung MW. Piscaglia F, et al. Among authors: ryoo by. Cancer. 2024 Apr 15;130(8):1281-1291. doi: 10.1002/cncr.35185. Epub 2024 Jan 23. Cancer. 2024. PMID: 38261521

10

Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma.

Kim HD, Park YG, Kim S, Kim KP, Park SR, Ryu MH, Ryoo BY, Yoo C. Kim HD, et al. Among authors: ryoo by. Hepatol Int. 2024 Jan 12. doi: 10.1007/s12072-023-10626-6. Online ahead of print. Hepatol Int. 2024. PMID: 38214792

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

250 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Results by year